Table 2 Clinicopathological characteristics of patients with adeno-NEPC
Characteristic | Only SYN (+) n = 12 | Not only SYN (+) n = 8 | P |
|---|---|---|---|
Age (years) | 66.00 ± 2.00 | 72.63 ± 2.12 | 0.041 |
T staging | Â | Â | 0.528 |
 T2 | 3 (25.0%) | 1 (12.5%) |  |
 T3 | 8 (66.7%) | 5 (62.5%) |  |
 T4 | 1 (8.3%) | 2 (25.0%) |  |
N staging | Â | Â | 0.142 |
 N0 | 7 (58.3%) | 2 (25.0%) |  |
 N1 | 5 (41.7%) | 6 (75.0%) |  |
M staging | Â | Â | 0.852 |
 M0 | 7 (58.3%) | 5 (62.5%) |  |
 M1 | 5 (41.7%) | 3 (37.5%) |  |
Gleason score | Â | Â | 0.798 |
 ≤ 7 | 2 (16.7%) | 1 (12.5%) |  |
 > 7 | 10 (83.3%) | 7 (87.5%) |  |
PSA (ng/L) | Â | Â | 0.224 |
 ≤ 20 | 2 (16.7%) | 0 (0.0%) |  |
 > 20 | 10 (83.3%) | 8 (100.0%) |  |
LDH (U/L) | Â | Â | 0.999 |
 < 250 | 9 (75.0%) | 6 (75.0%) |  |
 ≥ 250 | 3 (25.0%) | 2 (25.0%) |  |
ALP (U/L) | Â | Â | 0.798 |
 < 125 | 10 (83.3%) | 7 (87.5%) |  |
 ≥ 125 | 2 (16.7%) | 1 (12.5%) |  |